HB27, the HALT Fentanyl Act, amends the Controlled Substances Act to place fentanyl-related substances into Schedule I as a class, rather than controlling them one by one. The bill defines fentanyl-related substances broadly by chemical structure, covers salts and isomers where applicable, and allows the Attorney General to publish a list of substances that meet the definition without making that list the exclusive source of control. It also states that substances already controlled or separately listed in another schedule are not treated as fentanyl-related substances under this new schedule provision.
The bill also creates a streamlined research registration process for certain Schedule I research, especially for federally supported research or research tied to an investigational new drug exemption. It allows some researchers to begin work after notice rather than waiting for a full registration process, permits certain employees of a research institution to work under another researcher’s registration, allows a single registration for closely related sites in the same city or county, and reduces the need for repeat inspections in some cases. It further permits limited manufacturing activities incidental to research without a separate manufacturing registration, requires transparency if the Attorney General uses special procedures for particular substances, and directs the Attorney General to issue implementing rules within six months.
The bill also increases or clarifies criminal penalties by expressly tying fentanyl-related substances to existing Controlled Substances Act trafficking and import/export penalty provisions. It includes a technical correction to prior law and makes the amendments effective upon enactment, while preserving the government’s ability to treat pre-enactment conduct under existing analogue law. A sense-of-Congress provision states agreement with a prior court interpretation of the Controlled Substances Act.
Overall, the House vote suggests substantial support for the bill’s anti-trafficking and law-enforcement goals, as it passed 312-108. The earlier amendment vote was more divided, indicating some disagreement over the bill’s details even though the final passage was decisive. No committee transcript was provided, so the available record shows broad support for stronger fentanyl enforcement alongside some concern about the scope and mechanics of the legislation.
The main points of contention are likely the breadth of the fentanyl-related substance definition, the use of class scheduling, and the balance between enforcement and research access. Supporters would view the bill as a tool to close loopholes used by illicit manufacturers and traffickers, while critics may worry that the broad chemical definition could sweep in legitimate research compounds or create uncertainty for scientists and regulated entities. The bill attempts to address those concerns through expedited research procedures and transparency requirements, but those provisions themselves may also be debated as to whether they are sufficient.
Impact
HB27 would amend federal drug law by adding a class-based Schedule I category for fentanyl-related substances under the Controlled Substances Act and by updating related trafficking and import/export penalty provisions. It would also change DEA registration and inspection rules for research involving Schedule I substances, affecting researchers, research institutions, manufacturers, and distributors that handle fentanyl or fentanyl analogs. The bill’s provisions would apply upon enactment, with the Attorney General required to issue implementing rules within six months.
Sentiment
The general sentiment reflected in the voting history is strongly supportive of the bill’s core anti-fentanyl enforcement purpose, as shown by the 312-108 House passage vote. The failed amendment vote suggests there was meaningful debate over the bill’s specifics, but not enough opposition to prevent final passage. With no committee transcript available, the record indicates broad bipartisan concern about fentanyl trafficking, paired with some reservations about how the bill would operate in practice.
Contention
The most notable contention is over the breadth of the class scheduling approach for fentanyl-related substances. Opponents are likely to argue that the definition is expansive and could capture compounds beyond illicit fentanyl analogs, potentially affecting legitimate scientific research and creating compliance uncertainty. Supporters likely argue that a broad definition is necessary to keep pace with rapidly changing clandestine drug chemistry and to prevent traffickers from evading control by making minor structural changes. A second area of debate is whether the bill’s research-streamlining provisions adequately protect scientific work while still preserving diversion controls.
Related
Providing for consideration of the bill (H.R. 27) to amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.
Expressing the sense of the House of Representatives that illicit fentanyl-related substances are a weapon of mass destruction and should be classified as such, and recognizing President Trump's efforts to mitigate illicit narcotics from entering the United States through such actions as signing an Executive Order "Designating Fentanyl as a Weapon of Mass Destruction" and declaring the crisis caused by the rise of fentanyl a national health emergency.
Stopping Overdoses of Fentanyl Analogues ActThis bill permanently adds fentanyl-related substances to schedule I of the Controlled Substances Act. (A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires March 31, 2025.
Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.
Adding and removing certain substances in schedules I, III and IV of the uniform controlled substances act and making conforming changes to the criminal code definition of fentanyl-related controlled substances.